Study of Sac-TMT for advanced ovarian cancer without HRD
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IV ovarian cancer (or primary peritoneal or fallopian tube cancer) that is high-grade serous, high-grade endometrioid, clear cell, or certain mixed types.
- You had surgery to remove as much of the tumor as possible (debulking surgery) before or after chemo.
- You completed one round of platinum-based chemotherapy (like carboplatin or cisplatin) and it helped or kept the cancer stable.
- Your tumor is not HRD-positive (meaning it doesn't have a specific gene change that makes it more likely to respond to other treatments).
- You do not have active infections that need treatment, a history of severe eye disease, or uncontrolled heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests a targeted therapy called Sacituzumab for people with a rare type of ovarian cancer (clear cell carcinoma) whose cancer worsened after immunotherapy. The drug is designed to deliver chemotherapy directly to cancer cells, and researchers want to see if it can help when other treatments stop working.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, Sac-TMT and bevacizumab, as a second treatment option for people with advanced non-squamous non-small cell lung cancer whose cancer has gotten worse after initial chemotherapy and immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) for people with a specific type of non-small cell lung cancer that has spread to the brain and has stopped responding to a certain targeted therapy. The goal is to see if this combination can shrink brain tumors and improve outcomes.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.